Curated News
By: NewsRamp Editorial Staff
September 11, 2026
Life Sciences Virtual Investor Forum: Sept 17 Live
TLDR
- Investors gain direct access to seven life sciences companies advancing oncology, fibrosis, and antibiotics at the B2i Digital forum on September 17.
- B2i Digital hosts the Life Sciences Virtual Investor Forum online on September 17, featuring 30-minute company presentations, Q&A sessions, and on-demand replays.
- The forum highlights therapies for cancer, fibrosis, and infections, aiming to improve patient outcomes and global health through innovative life sciences.
- Learn about gold nanorod cancer therapy, cannabinoid medicines, and FDA-cleared 4D respiratory imaging at this free virtual investor event.
Impact - Why it Matters
This forum provides a rare opportunity for investors to hear directly from management teams across cutting-edge life science sectors, from photothermal cancer therapy to cannabinoid therapeutics and respiratory imaging. The live Q&A format allows investors to ask impromptu questions, gaining unfiltered insights that go beyond filings. For retail and institutional investors alike, this event offers a level playing field to assess emerging companies that are addressing unmet medical needs, potentially shaping future investment portfolios in high-growth biotech and medtech. Staying informed about these innovations can help investors identify long-term opportunities and risks in a rapidly evolving healthcare landscape.
Summary
B2i Digital, Inc. is inviting investors to the Life Sciences Virtual Investor Forum, a B2i Digital Featured Conference, taking place online on Thursday, September 17, 2026. Hosted by Virtual Investor Conferences, the event will feature live 30-minute presentations followed by audience Q&A, with replays available on demand. B2i Digital serves as the Official Marketing Partner, leveraging its media network and investor community to amplify each presenting company. The forum’s diverse lineup includes Sona Nanotech Inc. (photothermal cancer therapy using gold nanorods), Raphael Pharmaceutical (cannabinoid-based formulations for rheumatoid arthritis, chronic lung inflammation, and autoimmune disease), Amplia Therapeutics Ltd. (Focal Adhesion Kinase inhibitors for cancer and fibrosis), Adaptin Bio, Inc. (precision drug delivery technologies, including across the blood-brain barrier), Acurx Pharmaceuticals, Inc. (a new class of antibiotics targeting priority pathogens), CytoDyn Inc. (a humanized monoclonal antibody in solid-tumor oncology), and 4DMedical Ltd. (FDA-cleared four-dimensional respiratory imaging).
David Shapiro, CEO of B2i Digital, emphasized the value of live Q&A: “Reading company filings is a great cure for insomnia, but if you want to stay awake and hear it directly from management, these conferences are the best way to get a real feel for the company.” Registration is open via the Virtual Investor Conferences platform, and event details and presenting company profiles are available on the B2i Digital website. Virtual Investor Conferences, an OTC Markets Group Inc. property, connects public companies from global exchanges with investors. B2i Digital’s reach spans over 800 media outlets, 330 million monthly audience, and 70,000 opt-in email subscribers, supporting its Capital Markets Matchmaker℠ and From Marketing to Meetings℠ programs. The original release can be viewed on www.newmediawire.com.
Source Statement
This curated news summary relied on content distributed by NewMediaWire. Read the original source here, Life Sciences Virtual Investor Forum: Sept 17 Live
